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Abstract
Chronic Granulomatous Disease is the most commonly encountered immunodeficiency involving the phagocyte,
and is characterized by repeated infections with bacterial and fungal pathogens, as well as the formation of
granulomas in tissue. The disease is the result of a disorder of the NADPH oxidase system, culminating in an
inability of the phagocyte to generate superoxide, leading to the defective killing of pathogenic organisms. This
can lead to infections with Staphylococcus aureus, Psedomonas species, Nocardia species, and fungi (such as
Aspergillus species and Candida albicans). Involvement of vital or large organs can contribute to morbidity and/or
mortality in the affected patients. Major advances have occurred in the diagnosis and treatment of this disease,
with the potential for gene therapy or stem cell transplantation looming on the horizon.
Introduction
Primary immune deficiencies often present as recurrent
infections, often with unusual pathogens, or infections
of unusual severity or frequency. Host defense consists
of either nonspecific or specific mechanisms of immu-
nity to invading pathogens (Table 1). Nonspecific
mechanisms include barrier functions of skin and
mucosa (tears, saliva, mucosal secretions, mucociliary
responses, and clearance by peristalsis as occurs in the
bladder or the gastro-intestinal system), phagocyte
responses (neutrophils, macrophages or mononuclear
cells and their component of pathogen recognition
receptors or PRR and cell adhesion molecules or
CAMs), complement system of proteins, C reactive pro-
tein (CRP), cytokines, and the PRRs mentioned earlier
on the surface of a variety of cell types. Specific immune
responses include immunoglobulin class switching and
secretion by B lymphocytes/plasma cells and T lympho-
cyte responses (including antigen recognition, clonal
proliferation, and cytokine synthesis resulting in B cell
and phagocyte activation and survival).
Innate immunity occurs rapidly and is relatively non-
specific, while adaptive responses occur later and are
characterized by activation of the T and B lymphocytes,
antigen recognition, cognate interaction using several
key cell surface receptors (discussed later) and the
synthesis and secretion of antibodies, cytokines and
other effector molecules that lead to an expansion of
the specific immune response towards a pathogen
(Table 2). There are close interactions between the non-
specific/innate and adaptive immune responses, such
that a two-way response as well as independent
responses regulate overall immune function. To further
add a complex dimension to this process is the recent
discovery and description of several regulatory T cell
subsets including the T regulatory (T reg/Tr1 and Th3
subset) and the Th17 subset of lymphocytes that oversee
overall immune function. The description of these
aspects is beyond the scope of this review but needs to
be mentioned in order to understand phagocyte func-
tion and defects in CGD.
Primary immune deficiencies can involve either the
adaptive (T- and B-lymphocyte deficiencies) or the
innate (phagocyte, complement, or other defects)
immune response (Table 2). Of these, defects in phago-
cyte function constitute only about 18%, with the larger
portion of the defects seen in the B cell/antibody and/or
T cell components of immunity (Figure 1). These var-
ious defects are summarized in Figure 2, which
describes the potential sequence of events, starting from
T- and B cell interactions and antibody synthesis to the
involvement of phagocyte and complement components
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a given immune defect, susceptibility to a particular set
of pathogens is likely to occur, which can be explained
on the basis of the dominant immune response to any
specific pathogen. These aspects are summarized in
Table 3.
Disorders of the innate immune system involve defects
in complement as well as defective phagocyte responses
to infectious illness. In the latter group are a host of dis-
orders, which are summarized in Table 4. These include
chronic granulomatous disease (CGD), neutrophil adhe-
sion defects (such as the leukocyte adhesion deficiency
syndromes), Chediak-Higashi syndrome, Griscelli syn-
drome, Kostmann’s syndrome, WHIM syndrome (disor-
der characterized by myelokathexis), mannose binding
lectin deficiency (MBL deficiency), and enzymatic
defects within phagocytes such as deficiencies of glu-
cose-6-phosphate dehydrogenase (G6PD), glutathione
reductase, glutathione synthetase, and myeloperoxidase.
CGD is the most commonly encountered disorder of
phagocytes, and is characterized be repeated infections
with bacterial and fungal pathogens, as well as the for-
mation of granulomas in tissue. The disease is a disor-
der of the NADPH oxidase system, culminating in an
inability of the phagocyte to generate superoxide,
leading to the defective killing of pathogenic organisms.
As shown in Table 3, defects in phagocyte function lead
to infections with Staphylococcus aureus, Psedomonas
species, Nocardia species and fungi (such as Aspergillus
species and Candida albicans). Due to involvement of
vital or large organs, such infections can lead to signifi-
cant morbidity and/or mortality in the affected patients.
The following sections discuss the immunobiology of
phagocytes, the defects in CGD and the resulting clinical
spectrum observed.
Normal Phagocyte Physiology
Phagocytes include the neutrophils, monocytes, and
macrophages. Much of the early understanding of pha-
gocyte biology resulted from the work of Paul Ehrlich
and Metchnikov, pioneers who developed staining tech-
niques and methods to study these cells in vitro. The
term phagocytosis was probably introduced by Metchni-
kov. Hematopoietic growth factors such as GM-CSF and
M-CSF regulate phagocyte production from the bone
marrow, allowing the development of the monocyte-
macrophage lineage cell from the CFU-GM, shown in
Figure 3. The macrophage serves pleiotropic roles in the
immune response, including presenting microbial anti-
gen to the T cells in the context of major histocompat-
ibility complex, a phenomenon referred to as haplotype
restriction. T cells, especially the Th1 type cells, secrete
interferon gamma (IFN g) which activates macrophages,
which in turn express IL-12 and IL-18, thereby allowing
the proliferation of Th1 lymphocytes. Macrophage acti-
vation results in the activation of several processes,
aided partly by cognate T-macrophage interaction and
also by the PRRs such as the toll-like receptors. The
activation of macrophages results in functional
Table 1 Host Immune Defense Mechanisms
Non-Specific Specific
Barriers Humoral* (Antibodies)
Skin Cellular* (Lymphocytes)
Secretions (mucous, tears, saliva)
Mucociliary clearance
Peristalsis
Phagocytes
Complement
CRP and others
Cytokines
Pathogen recognition receptors*
*Major components affected in primary immune deficiency
Table 2 Innate and Adaptive Immunity
Feature Innate Adaptive
Action
Time
Early (hours) Late (days)
Cells Macrophage, DC, PMN, NK
cells
B and T cells
Receptors TLR: Fixed in genome Gene rearrangement BCRA,
TCR
Recognition Conserved molecules/PAMP Wide Variety
Evolution Conserved Only vertebrates
TLR = toll-like receptors; BCRA = B cell receptor for antigen; DC = dendritic
cells
PMN = polymorphonuclear leukocytes; B = B lymphocyte; T = T lymphocyte;
TCR = T cell receptor for antigen; PAMP = pathogen-associated molecular
patterns; NK cells = natural killer cells
Figure 1 Distribution of Common Immunodeficiencies. Primary
immune deficiencies can involve either the adaptive (T- and B-
lymphocyte deficiencies) or the innate (phagocyte, complement or
other defects) immune response (Figure 1). Of these, defects in
phagocyte function constitute only about 18%, with the larger
portion of the defects seen in the B cell/antibody and/or T cell
components of immunity.
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especially towards intracellular pathogens, and aided by
the expression of peroxides and superoxide radicals.
These processes are defective in CGD as will be dis-
cussed further. Other secretory effects of macrophages
result in the production of a plethora of mediators that
assist in immunity and are shown in Figure 3. Several of
these are also essential aspects of the antimicrobial func-
tion of the macrophages. The NADPH oxidase system is
pivotal to the anti-microbial function of the phagocyte
(neutrophil or macrophage) and its components need to
be discussed in some detail in order to understand the
molecular pathogenesis and classification of CGD. These
aspects are shown in Figure 4 and are discussed later.
Mechanisms Involved in CGD
CGD represents a heterogeneous group of disorders
characterized by defective generation of a respiratory
burst in human phagocytes (neutrophils, mononuclear
cells, macrophages, and eosinophils). The resultant
defect is an inability to generate superoxide and hence
an inability to contain certain infectious pathogens. The
disease manifests as repeated, severe bacterial and fungal
infections resulting in the formation of inflammatory
Table 3 Pathogen Patterns in Immune Deficiency
Pathogen Type T-cell Defect B-cell Defect Phagocyte Defect Complement Defect
Bacteria Bacterial sepsis Pneumococcus, Staphylococcus Neisseria
Haemophilus Pseudomonas Pyogenic bacteria
M. catarrhalis
Virus CMV, EBV, VZ CEMA ——
Fungi Candida/PCP PCP Candida, Aspergillus —
Parasite — Giardia ——
Acid Fast AFB — Nocardia —
CMV = Cytomegalovirus; EBV = Epstein-Barr virus; VZ = Varicella Zoster;
PCP = Pneumocystis Carinii; AFB = Acid-fast bacillus;
CEMA = Chronic Echovirus Meningoencephalitis of Agammaglobulinemia
M. catarrhalis = Moraxella catarrhalis
Figure 2 Defects Leading to Immunodeficiency Disease.T h ev a r i o u sd e f e c t sa r es u m m a r i z e di nF i g u r e2 ,w h i c hd e s c r i b et h ep o t e n t i a l
sequence of events, starting from T- and B cell interactions and antibody synthesis to the involvement of phagocyte and complement
components of the innate immune response. Explanation for the various aspects of the immune response is provided at the bottom of the
figure (components 1-8); Components 5 and 6 deal with phagocytic/neutrophil defects.
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Page 3 of 14granulomas. The earliest report of the disease was in
1954 by Janeway and colleagues [1]. Landing and Shir-
key [2] subsequently described a patient with recurrent
infection and associated histiocyte infiltration. A few
years later, Bridges and Good reported on a fatal granu-
lomatous disorder in boys and described this as a “new
syndrome” [3]. Since these early descriptions, a rather
amazing and accelerated understanding of the disease
and its molecular genetics have developed in the last 5
decades [4]. Several research groups reported on defec-
tive oxidative burst as a possible mechanism of the dis-
ease [5-8]. In 1966, Holmes and colleagues recognized
an abnormality of phagocyte function in the disease [9],
while in 1967 Quie and coworkers demonstrated defec-
tive in vitro killing of bacteria by phagocytes obtained
from patients with CGD [10]. In that same year, Baeh-
ner and Nathan described defective reduction of nitro-
blue tetrazolium by phagocytes from patients with CGD
during phagocytosis, and postulated this as a diagnostic
test [11]. This was a seminal paper that led to the criti-
cal test used to screen for the disease for decades [12].
This has now been replaced by a flow cytometric assay
for the oxidative burst. In 1968, Baehner and Karnovsky
demonstrated a deficiency of reduced nicotinamide-ade-
nine dinucleotide oxidase in patients with CGD [13].
This was followed by the demonstration of defective
superoxide generation from the phagocytes of patients
Table 4 Disorders of the Phagocyte Resulting in Immune
Deficiency
￿ Chronic granulomatous disease (CGD)
￿ Neutrophil adhesion defects (such as the leukocyte adhesion
deficiency syndromes),
￿ Chediak-Higashi syndrome
￿ Griscelli syndrome
￿ Kostmann’s syndrome
￿ WHIM syndrome (disorder characterized by myelokathexis)
￿ Mannose binding lectin deficiency (MBL deficiency)
￿ Enzymatic defects within phagocytes- deficiencies of:
○ Glucose-6-phosphate dehydrogenase (G6PD)
○ Glutathione reductase, glutathione synthetase
○ Myeloperoxidase
Figure 3 Role of Macrophages in Host Defenses. Macrophages are generated from bone marrow precursor cells in the presence of stem cell
hematopoietic factors (such as granulocyte-macrophage colony stimulating factor/GM-CSF and macrophage colony stimulating factor/M-CSF).
The activation of macrophages (in the presence of specific receptors and T lymphocytes as shown in the figure- CD40/CD40L, CD28/B7,
interleukin-interleukin receptor etc) results in functional consequences such as microbicidal activity directed especially towards intracellular
pathogens and aided by the expression of peroxides and superoxide radicals. These processes are defective in CGD (see text). Other secretory
effects of macrophages result in the production of a plethora of mediators that assist in immunity (these are shown in the figure and include
complement, enzymes, interleukins, interferons and growth factors).
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defective NADPH oxidase expression in the disease by
Hohn and Lehrer [15]. In 1986, Baehner reported on
the gene localization for X-linked CGD to xp21 [16,17].
Subsequently, defects in several components of the
NADPH oxidase complex, including the gp91
phox,p 2 2
phox [18], p67
phox [18], and p47
phox [19] were described
by various researchers.
The presumed mechanism of CGD and the associated
d e f e c t si nN A D P Ho x i d a s es y s t e ma r es h o w ni nF i g u r e
4. The assembly of the various subunits of NADPH oxi-
dase is shown in the figure, while the molecular genet-
ics, rough prevalence, inheritance pattern, and
chromosomal localization are shown in the bottom of
the figure. There are several components of NADPH
oxidase: of these the cytochrome-b558 heterodimer is
located in the membrane and consists of the gp91
phox
and p22
phox units [4,20,21], while three cytosolic compo-
nents exist- including the p67
phox ,p 4 7
phox ,a n da
p40
phox. Following cellular activation, the soluble cytoso-
lic components, p67
phox, p47
phox, and a p40
phox, move to
the membrane and bind to components of the cyto-
chrome-b558 heterodimer. This is also accompanied by
the binding of the GTPase protein, Rac, culminating by
unclear mechanisms in flavocytochrome activation. This
catalyzes the transfer of electrons from NADPH to oxy-
g e n ,r e s u l t i n gi nt h ef o r m a t i o no fs u p e r o x i d ei nt h e
extracellular component as shown in Figure 4. Subse-
quent reactions via superoxide dismutase (SOD), cata-
lase or myeloperoxidase (MPO), occurring in the
phagolysome, can result in formation of H2O2,H 2O, or
HOCl
- respectively. Recent data suggest that the forma-
tion of superoxides and reactive oxygen species is not
t h ee n d - a l lo ft h e s er e a c t i o ns, as such mediators may
also set off subsequent activation of granule proteins
such as cathepsin G and elastase, leading to further ela-
boration of the immune-inflammatory response, all of
which are therefore likely to be defective in CGD.
Molecular subtypes and Genetics of CGD
X-linked CGD (XL-CGD) arises due to mutations in the
gp91
phox gene and is responsible for 65-70% of the clinical
cases in the United States [17,22-24]. This gene is termed
CYBB and spans a 30 kb region in the Xp21.1 region (Fig-
ure 4). Deletions, frameshift, missense, nonsense, and
splice site mutations have been described in this gene.
Figure 4 The NADPH Oxidase System. The assembly of the various subunits of NADPH oxidase is shown in the figure, while the molecular
genetics, rough prevalence, inheritance pattern and chromosomal localization of CGD subtypes are shown in the bottom of the figure. There
are several components of NADPH oxidase: of these the cytochrome-b558 heterodimer is located in the membrane and consists of the gp91
phox
and p22
phox units, while three cytosolic components exist- including the p67
phox , p47
phox and a p40
phox. Following cellular activation, the
soluble cytosolic components, p67
phox , p47
phox , and a p40
phox , move to the membrane and bind to components of the cytochrome-b558
heterodimer. This is also accompanied by the binding of the GTPase protein, Rac, culminating by unclear mechanisms in flavocytochrome
activation. This catalyzes the transfer of electrons from NADPH to oxygen, resulting in the formation of superoxide in the extracellular
compartment (phagolysosome). Subsequent reactions via superoxide dismutase (SOD), catalase or myeloperoxidase (MPO), occurring in the
phagolysome, can result in formation of H2O2,H 2O or HOCl
- respectively.
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gene occur, this may result in a so-called “Contiguous
gene syndrome”. This may result in associations of the
Kell phenotype/Mcleod syndrome with X-linked chronic
granulomatous disease (CGD; OMIM 306400), Duchenne
muscular dystrophy (DMD; OMIM 310200), and X-linked
retinitis pigmentosa (RP3; OMIM 300389)[25,26].
Autosomal recessive CGD (AR-CGD), seen in the
remaining 35% cases, arise due to mutations of the
other components of the NADH oxidase (except p40
phox
and Rac which are yet to be associated with any CGD
phenotype) [22]: these include- p22
phox ,p 6 7
phox and
p47
phox . Of these, the dominant mutations observed is
of the p22
phox gene which accounts for almost 25%
cases. The chromosomal location, MIM number, inheri-
tance, and frequency are shown in Figure 4. These phe-
notypes can be referred to as the X-CGD and as the
A22/A47/A67 CGD. Of these subtypes, A47 patients
appear to have a less severe course. Nevertheless,
extreme heterogeneity may be seen in the manifestations
of this disease. Perhaps concomitant immune defects
such as those of IgA deficiency or mannose binding lec-
tin mutations (MBL) might be responsible for some of
the observed heterogeneity in severity and/or disease
progression. These aspects need further study.
Clinical Features
Patients with CGD usually present in infancy or child-
hood with repeated, severe bacterial and/or fungal infec-
tions. However, delayed diagnosis in adulthood is also
possible as is occurrence in females. The disease is rela-
tively uncommon, affecting about 1/250,000 individuals.
The most common manifestations include infection,
granulomatous disease, inflammation, and failure to
thrive (nutritional effects of chronic infection and
inflammation). The disease is heterogeneous in its mani-
festations, related to the subtypes, and severity of the
associated macrophage defect [22]. In the majority of
patients, the production of superoxides is undetetectable
and the manifestations are therefore early and predict-
able to a great extent. In others, low level respiratory
burst activity may delay manifestations or diagnosis into
early adulthood [27-30]. Most patients present with
infectious illness, which include sinopulmonary disease,
abscesses, or lymphadenitis. Other manifestations are
related more to inflammatory consequences and/or
structural disease and resultant organ dysfunction.
The following sections will discuss the clinical aspects of
CGD (X-linked disease and the autosomal recessive dis-
ease counterparts), the Kell-deletion/Mcleod syndrome,
association with MBL deficiency and other deficiencies
and rare clinical manifestations of the carrier state.
Clinical Aspects
CGD presents most often with infectious illness, though
some patients may present with a failure to thrive, gran-
ulomatous complications, or inflammatory disease. The
disease is usually diagnosed in childhood and sometimes
in early adulthood. Table 5 lists the infectious and Table
6 the inflammatory consequences of CGD. Over 90% of
the patients with confirmed CGD have severe respira-
tory burst defects resulting in little or no expression of
superoxide radicals. These patients usually present early
in life (usually in infancy) as severe or life threatening
Table 5 Infectious Consequences of CGD
Type Organ
System
Manifestations Etiology Diagnosis
Infectious
Blood
stream
Sepsis B Cepacia Pseudomonas Serratia Staphylococcus Salmonella Blood cultures
Echocardiogram
Pulmonary Pneumonia Aspergillus Nocardia Serratia Pseudomonas Staphylococcus Klebsiella
Candida Others
Radiolology Cultures Biopsy
Cutaneous Impetigo Abscess Staphylococcus Klebsiella Aspergillus/Candida Serratia Aspirate cultures Biopsy
Lymph
node
Adenitis
Adenopathy
Candida/Nocardia Aspergillus Serratia/Klebsiella Fine needle aspirate Cultures
Biopsy
Liver Abscess Staphylococcus Streptococcus Aspergillus/Nocardia Serratia Ultrasound or CT Aspirate
Biopsy
Bone Osteomyelitis Serratia, Aspegillus Staphylococcus Pseudomonas/Nocardia Bone scan CT/Biopsy
GI Tract Perirectal abscess
Fistulae
Enterobacteriaceae Staphylococcus Biopsy Cultures
Urinary Pyelonephritis Enterobacteriaceae Cultures IVP/CT etc
CNS Meningitis Brain
abscess
Candida, Haemophilus Aspergillus Staphylococcus LP, cultures CT/MRI Biopsy
CT = computerized tomography; MRI = magnetic resonance imaging; LP = lumbar puncture; IVP = intravenous pyelogram; CNS = central nervous system; GI =
gastrointestinal
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Page 6 of 14bacterial or fungal infections. On the other hand, some
patients might present in late childhood or early adult-
hood with recurrent and unusual infections, leading to
the diagnosis. Typical infections include purulent bacter-
ial infections (such as pneumonias, sinusitis or liver
abscess) or necrotizing fungal infections of deep tissue
or bone. As shown in Table 5, common pathogens
include the gram negative Enterobacteriaciae, Staphylo-
coccus, Nocardia, Aspergillus, Candida and atypical
Mycobacteria [31,32]. Other bacterial include- Burkhol-
deria species and Chromobacterium violaceum.M a n y
apparent infections go undetected on cultures and may
require special efforts to determine a specific etiological
organism. At least in Sweden, patients with X-linked
disease had more infections than the AR counterparts,
with dermal abscesses morec o m m o n l ys e e nt h a nl y m -
phadenitis or pneumonias [33]. In the Japanese experi-
ence at one hospital, of 23 patients treated, nearly half
had Aspergillus infection of the lungs, while short staure
and underweight were a complication in up to 1/5
th of
the patients [34]. Failure to thrive was also observed in
the UK series reported [35], where the incidence of
growth failure was much higher and listed at 75%.
Aspergillus as a major cause of morbidity and mortality
was also observed in the German cohort [36], where
patients with severe involvement of cytochrome b558
were the most likely to manifest complications at an
early age and also suffer from more infections compared
to those with AR disease. Liese and coworkers described
11 patients with delayed presentations and diagnosis as
late as 22 years of age, of which eight had X-linked dis-
ease but residual cytochrome function and three had the
AR disease, while nine out of the eleven patients had
some residual production of reactive oxygen metabolites,
explaining their delayed presentation [37]. In a European
cohort study consisting of 429 patients [38], 67% had X-
linked disease and 33% had the AR counterpart. The
patient population consisted of 351 males and 78
females [38]. According to retrospective data collected
in this series of patients, AR disease was diagnosed later
and the mean survival time was significantly better in
these patients (49.6 years) than in XL disease (37.8
years), compatible with other reports from the United
States and elsewhere. Pulmonary (66% of patients), der-
matological (53%), lymphatic (50%), alimentary (48%),
and hepatobiliary (32%) complications were the most
frequently observed [38]. Staphylococcus aureus, Asper-
gillus spp, and Salmonella spp. were the most common
cultured pathogens in that order, while Pseudomonas
spp. and Burkholderia cepacia were rarely observed.
Roughly 3/4
th of the patients received antibiotic prophy-
laxis, 1/2 antifungal prophylaxis, and 1/3
rd-received
gamma-interferon. Less than 10% of the patients had
received stem cell transplantation. Bacterial pneumonia
and/or pulmonary abscess, systemic sepsis and brain
abscess were the leading causes of death in this series.
The differences between the European and United States
data/observations are shown in Table 7.
Winkelstein and coworkers reported on the United
States CGD experience [30]. Of the 368 patients regis-
tered, 259 had the XL-CGD, 81 had AR-CGD, and in the
remaining cases the mode of inheritance was unknown.
Pneumonia, suppurative adenitis, subcutaneous abscess,
Table 6 Inflammatory and Structural Complications of
CGD
Frequency Complication
>50%/
Frequent
Lymphadenopathy
Hepatosplenomegaly
Anemia
Hyperglobulinemia and APR Failure to thrive,
underweight
Failure to thrive, underweight
≤50% Diarrhea
Gingivitis
Hydronephrosis
Gastric outlet obstruction
Granulomatous ileocolitis
Stomatitis
Granulomatous cystitis
Pulmonary fibrosis
Esophagitis
Glomerulonephritis
Chorioretinitis
Discoid lupus
Table 7 Differences between United States and European
Data
Feature US European
Number (n) 368 (259 XL/81 AR-
CGD)
429 (67% XL- and 33%
AR-CGD)
Pneumonia 79% 66%
Suppurative adenitis 53% 50%
Subcutaneous
abscess
52% 53%
Liver abscess 27% 32%
Osteomyelitis 25% NA
Sepsis 18% NA
Gastric outlet
obstruction
15% NA
Urinary tract
obstruction
10% NA
Colitis/GI tract 17% 48%
Mortality 18% NA
XL = x-linked; AR = autosomal recessive
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quently observed complications, in that order (Table 8).
Other complications (Table 6) included gastric outlet
obstruction, urinary tract obstruction, and granuloma-
tous colitis or enteritis. A small fraction of the XL- and
AR-CGD kindreds reported the occurrence of lupus in
family members. The most common causes of death
were pneumonia and/or sepsis due to Aspergillus or Bur-
kholderia cepacia. As noted earlier and confirmed in the
United States experience, patients with XL-CGD had a
more severe phenotype than those with the AR form of
the disease.
Sinopulmonary Complications
Pneumonia as stated earlier is often the most common
complication of the disease. Infections with catalase-
positive organisms are the rule. In many cases, no
organism is cultured even though the patients are often
treated with and respond to antimicrobials directed
against bacteria or fungi. The diagnosis of pulmonary
involvement is most often made clinically, complemen-
ted by radiology (chest roentgenography, computerized
tomography or MRI), biopsy, and cultures. Airway
obstruction that sometimes complicates infection/granu-
lomatous disease is best diagnosed by pulmonary func-
tion tests and by bronchoscopy. Recurrent pneumonia,
lung abscess, effusions and empyema thoracis, mediast-
inal adenopathy, and necrotizing nodular disease may be
seen [30]. The common pathogens include Staphylococ-
cus aureus, Burkholderia cepacia, Serratia marcescens,
Nocardia,a n dAspergillus spp. In the series reported by
Winkelstein et al., pneumonia accounted for 79% of the
infectious complications of CGD [30]. Genetically, var-
iant alleles of mannose binding lectin (MBL) were asso-
ciated with autoimmune disea s ea n dm a yp r e d i s p o s et o
some pulmonary complications [39]. Chest wall invasion
by pathogens has also been described [40] and may be
due to necrotizing infections by fungi such as Aspergil-
lus [41]. Pulmonary infections have also been described
due to Pneumocystis carinii [42-44], Cryptococcus neo-
formans [45], Aspergillus [41,46-50], visceral Leishma-
niasis [51], suppurative pathogens [52], Pseudomonas
cepacia [53,54], [55], Legionella [56,57], Nocardia
[58-61], Mycoplasma pneumoniae [62], Sarcinosporon
inkin-a skin fungus [63], Tuberculosis [64], Trichosporon
pullulans [65,66], Tularemia [67], Q Fever [68], Acremo-
nium kiliense [69], Botryomycosis [70], Chrysosporium
zonatum [71], Burkholderia (Pseudomonas) gladioli [72],
fulminant mulch/filamentous fungi [73], Respiratory
Syncitial Virus [74], and Francisella philomiragia (for-
merly Yersinia philomiragia)[ 7 5 ] .C e r t a i np n e u m o n i c
variants have also been described in CGD, including
crystalline, nodular, and eosinophilic pneumonias
[76,77].
Ocular Complications
Blepharokeratoconjunctivitis, marginal keratitis, and
choroido-retinal scars have all been described in CGD
[78,79]. A case of congenital arteriovenous hemangioma,
presumably related to defective phagocyte function and
hemosiderin removal, was described in a patient with
CGD [80].
Neurological Complications
Patients with CGD can develop several neurological
complications. Brain abscess has been well described in
patients with CGD. Various pathogens have been asso-
ciated with brain abscess development including Sce-
dosporium prolificans [81], Alternaria infectoria [82],
Salmonella enterica subspecies houtenae [83], and
Aspergillus [84,85]. Other complications associated
with CGD include white matter disease [86], CNS
granulomatous disease [87] and leptomeningeal, and
focal brain infiltration by pigmented, lipid-laden
macrophages [88]. Several reports of fungal brain infec-
tion [89], Aspergillus abscess resembling a brain tumor
[90], spinal cord infection by Aspergillus [91] and fun-
gal granuloma of the brain have been described [92].
Meningitis due to Streptococcus [93] and Candida [94]
has also been reported on.
Hepatobiliary and GI Complications
A plethora of GI tract complications occur in CGD. As
stated earlier, variant alleles of mannose binding lectin
(MBL) were associated with autoimmune disease while
polymorphisms of myeloperoxidase and Fc g RIII were
associated more with gastrointestinal complications in
patients with CGD [39]. As summarized by Barton et
al., GI tract disorders can present from the mouth to
the anus, and can be characterized by ulcers, abscesses,
fistulae, strictures, and obstructive symptoms [95].
Inflammatory granulomatous colitis can also lead to
obstructive disease, diarrhea, malabsorption, or other
Table 8 Differences between the XL and AR forms of
CGD*
Feature XL CGD AR CGD
Family history of lupus 10% 3%
Age at diagnosis 3.01 years 7.81 years
Perirectal abscess 17% 7%
Suppurative adenitis 59% 32%
Bacteremia and/or fungemia 21% 10%
Gastric outlet obstruction 19% 5%
Urinary obstruction 11% 3%
Mortality (over 10 year observation) 21.2% 8.6%
*Adapted from reference 30 (XL = x-linked; AR = autosomal recessive)
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monella enteritis, and acalculous cholecystitis have been
described, some requiring surgical intervention [96,97].
Gastric outlet obstruction is a recognized complication
[98-102]. A case of gastric outlet obstruction due to dif-
fuse gastric infiltration has also been described [103].
There have been reports of nonsurgical resolution of
gastric outlet obstruction following the use of glucocor-
ticoids and antibiotics [104]. Liver involvement in the
form of hepatic granuloma or multiple hepatic abscesses
can complicate management [105-112].
Hepatic involvement by Staphylococcus aureus and
Pseudomonas cepacia can manifest as granuloma or
abscess formation [113]. A rare case of ascites has been
described in CGD [114] and non-cirrhotic portal hyper-
tension was reported to have prognostic significance
[115]. In one study of 194 patients from the NIH, ele-
vated liver enzymes (mainly transaminitis) were docu-
mented in >75%, liver abscess in 35%, hepatomegaly in
34%, and splenomegaly in over 50% cases [116]. Liver
histology demonstrated granuloma in 75% and lobular
hepatitis in 90%. Venopathy of the portal vein was
observed in 80% and was associated with splenomegaly
[116]. Ament and Ochs commented on the occurrence
of several gastrointestinal manifestations in patients with
CGD [117,118]- including granulomata on biopsy,
malabsorption syndromes, and B12-deficiency. Inter-
feron gamma therapy, careful use of glucocorticoids and
liver transplantation have improved outcomes in some
patients with liver involvement [119,120]. Chronic infec-
tion, nausea, vomiting, and malabsorption can lead to
weight loss and/or failure to thrive in patients with
CGD [70,95,121-123]. Catch up growth tends to occur
and many patients attain predicted heights by late ado-
lescence [124].
Renal and Gentourinary Complications
Granulomatous involvement and/or infectious complica-
tions can result in major genitourinary complications in
patients with CGD. Use of glucocorticoids and antimi-
crobials has resulted in remission of obstructive pathol-
ogy in some patients, thereby avoiding surgery. Frifeit
and coworkers described chronic glomerulonephritis in
a 12 year old male with CGD [125]. This culminated in
terminal uremia and fatal pulmonary Aspergillosis and
Pseudomonas septicemia. Diffuse infiltration of renal
and other tissues by pigment-containing macrophages
may also result in pathology in CGD [126]. Renal Asper-
gilloses resulting in renal abscess formation has also
been described [127] as well as xantogranulomatous
pyelonephritis and renal amyloidosis [128,129]. In the
latter case, renal amyloidosis resulting in nephritic syn-
drome occurred in a patient with CGD post-renal trans-
plantation [129]. In one series, 23/60 patients (38%)
with CGD demonstrated urological disease [130],
including bladder granulomas, urethral strictures, recur-
rent urinary tract infections, and renal dysfunction. The
judicious use of glucocorticoids and interferon gamma
has had a beneficial effect on several of these conditions
of either the genitourinary or gastrointestinal systems.
Other Complications
Dermatological manifestations in patients with CGD
include atopic dermatitis-like disease but with systemic
or deep seated infections [131], facial granulomata [132]
and discoid lupus, and seborrheic dermatitis-like disease
[133]. Vesicular and granulomatous of fungal skin
lesions have been observed in small reports [134].
Altered skin Rebuck window responses in patients with
CGD have been recorded [135]. Several skeletal compli-
cations related mainly to infections have been described
in patients with CGD. Osteomyelitis secondary to inva-
sive Aspergillus or Burkholderia gladioli [136-140] may
occur. Osteomyelitis may involve either the long bones
or even the spine [137,139]. Dactylitis may complicate
CGD [141]. Multifocal osteomyelitis secondary to Paeci-
lomyces varioti has also been reported [142] as has
sacral osteomyelitis secondary to Basidiomycetous fungi
such as Inonotus tropicalis [143]. Gill et al., reported on
a favorable response to Interferon gamma in osteomyeli-
tis complicating CGD [144]. Occasionally recombinant
hematopoietic growth factors (rhG-CSF), long term anti-
microbials, and surgery may be required in the manage-
ment of these complex patients [140,145].
Inflammatory Responses in CGD
Table 6 lists the inflammatory and structural changes
observed in CGD. Some of these changes may truly
represent infectious complications, but as stated earlier,
many such tissues fail to grow any identifiable patho-
gens in culture. These changes may also represent the
exuberant inflammatory response seen in the disease.
Whether these changes represent an overwhelming
response to infection by other intact components of the
immune response (such as T cells and B cells) and man-
ifested by hyperglobulinemia and elevated acute phase
reactants, a failure of the compensatory “anti-inflamma-
tory response” [146], a diminished production of specific
regulatory products such as PGE2 [147] or activation of
nuclear factor kappaB, the ubiquitous transcription fact
[148] is unclear. This in addition to the poor superoxide
radical response [149,150], failure of phagocytosis and
the enhanced cytokine responses [151] may be responsi-
ble for the observed inflammatory pathologies listed in
Table 6. At least in a murine model, the failure of an
immune-modulatory effect of superoxide radicals was
associated with exuberant inflammatory responses and
TH17-mediated pathology and arthritis [152]. The
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“hyperinflammation” further will improve our under-
standing of the immune dysregulation seen in the dis-
ease [153,154]. Granuloma formation is often
accompanied by inflammatory, obstructive, or functional
impairments of organ systems, such as the GI tract or
the GU system [155].
Other Aspects of CGD
In some patients with CGD, the deletion in the Xp21
can extend to other “contiguous” genes resulting in an
association of the disease with lack of Kell blood anti-
gens (Mcleod phenotype), Retinitis Pigmentosa, and
Duchenne Muscular Dystrophy [156-159]. This could
complicate blood transfusion. There have been reports
of successful granulocyte transfusions in patients with
the Mcleod Phenotype, complicated only by mild hemo-
lysis [160].
Female carriers have manifested some symptoms, such
as dermatitis, stomatitis, and discoid lupus-like disease
[161-165]. CGD-like infections can sometimes present
in female carriers, and these patients demonstrate both
normal and CGD-neutrophils with functional mosaicism
[166]. In one report of 15 carriers of the CGD gene, five
patients had both stomatitis and discoid SLE-like lesions
and five patients had stomatitis alone, while the remain-
ing five patients were relatively asymptomatic [167].
Martin-Villa and co-workers also described more fre-
quent autoantibodies among carriers of the CGD gene
compared to non-carrier relatives, probably related to
random X-chromosome inactivation [168].
Concomitant immune deficiencies may complicate
CGD and contribute to infectious complications. In
patients with documented CGD, variant alleles of man-
nose binding lectin (MBL) were associated with autoim-
m u n ed i s e a s ea n dm a yp r e d i s p o s et os o m ep u l m o n a r y
complications [39]. There have been several reports of
IgA deficiency in patients with CGD [55,169,170].
Further studies of humoral immune response and MBL
deficiency in patients with CGD are essential to further
understand these immune interactions and predisposi-
tion to autoimmunity and infectious disease.
Diagnosis and Treatment
The approach to the diagnosis of CGD is shown in
Table 9. Many of the clinical and laboratory abnormal-
ities suggest the diagnosis. The confirmatory test is mea-
surement of the oxidative burst (superoxide production)
of the neutrophil in response to stimulation. While the
NBT slide test was commonly used in the past
[11,12,171-173], this has been replaced recently by the
dihydrorhodamine 123 (DHR) and flow cytometric ana-
lysis- the DHR test [174,175]. The DHR test has the
ability to distinguish X-linked from the AR forms of the
Table 9 Approach to Diagnosis of CGD
Clinical information
1. Severe, recurrent pulmonary and hepatic infections including
abscess formation
2. Specific etiologic pathogens such as B. cepacia, Nocardia,
Aspergillus etc
3. Granulomatous lesions of the GI tract or the GU system
Laboratory abnormalities
1. Anemia
2. Polyclonal hyperglobulinemia
3. Elevated acute phase reactants such as ESR or CRP
4. Normal studies of T and B lymphocyte immunity
Diagnostic test
1. NBT test (no longer used)
2. DHR
Molecular tests
1. Immunoblotting or flow cytometry
2. Molecular techniques including gene sequencing and mutational
analyses for subtype
NBT = nitroblue tetrazolium slide test; ESR = erythrocyte sedimentation rate;
CRP = C reactive protein; GI = gastrointestinal system; GU = genitourinary
system
Table 10 Treatment of Chronic Granulomatous Disease
Prophylaxis of
Infection
Antibacterial
therapy
Trimethoprim-sulfamethoxazole (TMP-SMX) 5
mg/kg/day (based upon the TMP component,
maximum dose 320 mg P.O in two divided daily
doses) [187]
Antifungal therapy Itraconazole 5 mg/kg [85] (maximum dose 200
mg orally daily)
Immunomodulatory
therapy
Interferon-gamma (IFN-g) [85,137] 50 μg/m
2
(subcutaneous) three times a week 1.5 μg/Kg
(subcutaneous) three times a week for children
<0.5 m
2
Management of
Infection
Empirical treatment TMP-SMX/Fluoroquinolone/Antifungal
(Voriconazole)
￿ Burkholderia, Serratia species: TMP-SMX
￿ Nocardia species: TMP-SMX and/or
Cabapenem
￿ Staphylococcus aureus:TMP-SMX or
Vancomycin
￿ Fungal infection: Antifungal agent ±Steroid
Liver abscess Surgical excision [111]; IFN g [108,120]
Granulocyte
Transfusion
Unirradiated white blood cells [183,184]
Definitive
treatment
Stem cell transplant HLA identical sibling umbilical cord stem cell
transplantation (UCSCT) after myeloablative
conditioning (Stem cell transplantation from a
HLA-identical donor may, at present, be the only
proven curative approach to CGD) [185-187]
Gene therapy Still experimental [188-192]
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Other tests proposed include denaturing high-perfor-
mance liquid chromatography (DHPLC) system [179]
and real time PCR-based assays [180,181]. Molecular
mutational analysis can help confirm the diagnosis,
define the defect, and classify the patient into specific
subtypes.
Treatment of CGD includes prophylaxis of infections
using interferon gamma and appropriate antimicrobials
(such as trimethoprim sulfamethoxazole/TMP-SMX and
itraconazole), and management of infections using appro-
priate antimicrobials based on pathogen likelihood or
identification. In select situations, granulocyte transfusions
may be required [182-184]. The roles for stem cell trans-
plant (HLA identical sibling umbilical cord stem cell trans-
plantation (UCSCT) after myeloablative conditioning
[185-187]) and gene therapy need to be defined [188-192].
Allogeneic hematopoietic stem cell transplantation from a
HLA-identical donor may, at present, be the only proven
curative treatment for CGD [187]. Summaries of various
treatment options are provided in Table 10.
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